Data gathered: November 23
AI Stock Analysis - Esperion Therapeutics (ESPR)
Analysis generated March 24, 2024. Powered by Chat GPT.
Esperion Therapeutics is a biopharmaceutical company dedicated to the research, development, and commercialization of therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C) in the backdrop of statin intolerance or insufficient treatment response. The company's flagship products are designed to address significant needs in the lipid management space. The drug development focus on specific patient subsets within the broader cardiovascular disease market is crucial, as these patients often have limited options available.
Stock Alerts - Esperion Therapeutics (ESPR)
 |
Esperion Therapeutics | November 21 Insider Alert: Warren Eric is selling shares |
|
Esperion Therapeutics | November 19 Price is up by 5.6% in the last 24h. |
|
Esperion Therapeutics | November 14 Price is down by -5.4% in the last 24h. |
|
Esperion Therapeutics | November 13 Price is down by -5.1% in the last 24h. |
Alternative Data for Esperion Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 10 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 11,000 | Sign up | Sign up | Sign up |
| Employee Rating | 72 | Sign up | Sign up | Sign up |
| Google Trends | 30 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 78 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 8,703 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,142 | Sign up | Sign up | Sign up |
| Twitter Mentions | 8 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 69 | Sign up | Sign up | Sign up |
| Linkedin Employees | 339 | Sign up | Sign up | Sign up |
About Esperion Therapeutics
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.
| Price | $2.52 |
| Target Price | Sign up |
| Volume | 3,160,000 |
| Market Cap | $487M |
| Year Range | $1.61 - $3.24 |
| Dividend Yield | 0% |
| Analyst Rating | 75% buy |
| Industry | Drug Manufacturers |
In the news
 |
Esperion Therapeutics (NASDAQ:ESPR) Downgraded by StockNews.com to HoldNovember 18 - ETF Daily News |
 |
Esperion Therapeutics: Growth Initiatives Are Paying Off - BuyNovember 12 - SeekingAlpha |
 |
Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...November 7 - Yahoo |
Esperion Therapeutics : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)November 7 - Finnhub |
|
 |
Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call TranscriptNovember 6 - SeekingAlpha |
 |
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue EstimatesNovember 6 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 52M | 40M | 12M | -30M | -16M | 0.000 |
| Q2 '24 | 21M | 44M | -24M | -62M | 2.6M | -0.330 |
| Q1 '24 | 124M | 42M | 82M | 61M | 72M | 0.340 |
| Q4 '23 | 17M | 45M | -28M | -56M | -42M | -0.500 |
| Q3 '23 | 19M | 33M | -14M | -41M | -28M | -0.370 |
Insider Transactions View All
| Warren Eric filed to sell 162,355 shares at $2.2. November 20 '24 |
| Warren Eric filed to sell 162,552 shares at $2.1. October 18 '24 |
| Warren Eric filed to sell 162,659 shares at $1.8. September 18 '24 |
| Koenig Sheldon L. filed to sell 752,266 shares at $1.8. September 18 '24 |
| Warren Eric filed to sell 165,267 shares at $1.9. August 20 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$155.17 0% | 51 |
 |
Eli Lilly and CompanyLLY |
$748.01 0% | 64 |
 |
PfizerPFE |
$25.65 0% | 47 |
 |
AstrazenecaAZN |
$65.63 0% | 71 |
 |
AbbVieABBV |
$176.95 0% | 59 |
Read more about Esperion Therapeutics (ESPR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Esperion Therapeutics?
The Market Cap of Esperion Therapeutics is $487M.
What is the current stock price of Esperion Therapeutics?
Currently, the price of one share of Esperion Therapeutics stock is $2.52.
How can I analyze the ESPR stock price chart for investment decisions?
The ESPR stock price chart above provides a comprehensive visual representation of Esperion Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Esperion Therapeutics shares. Our platform offers an up-to-date ESPR stock price chart, along with technical data analysis and alternative data insights.
Does ESPR offer dividends to its shareholders?
As of our latest update, Esperion Therapeutics (ESPR) does not offer dividends to its shareholders. Investors interested in Esperion Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Esperion Therapeutics?
Some of the similar stocks of Esperion Therapeutics are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.